Abstract
Introduction
Autologous conditioned serum (ACS) is a novel blood product developed for intra-articular
injection as a novel therapy for Osteoarthritis (OA).
This study is a retrospective evaluation of 28 cases (25 Knee-OA and 3 hip-OA) treated
with ACS between November 2013 and February 2016.
Materials and methods
ACS was prepared according to standards in an accredited Cell Manipulation Lab, and
applied by an expert clinician (2 ml injection once weekly over 4 weeks). At any injection
visit (Timepoints 1–4), and after a follow-up of 1 (Timepoint 5) and 6 months (Timepoint
6), patients were asked to describe the intensity of their pain with the VAS (visual
analog scale) psychometric scale, and the objective parameter ROM (Range Of Motion)
was recorded in case of injection in the knee.
Results
Pain (VAS) reduced in all cases since the first injection up to Timepoint 5.
A significant improvement was observed in VAS between Timepoint 1 and 6 (primary objective),
with a median VAS decrease of 60 mm (range 20–100, p < 0.01).
A significant difference was also recorded in ROM between Timepoint 1 and 6 (secondary
objective), with a median increase of 25° (range 5–40, p < 0.01).
Ten out of 14 patients (71%) who were undergoing a chronic therapy to relieve pain
were able to interrupt it. No serious adverse events were recorded.
Conclusions
Treatment with ACS produced a rapid decline in pain, accompanied by a large improvement
in ROM. These results suggest that ACS is a valid option for the treatment of OA.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Blood-derived biomaterials and platelet growth factors in regenerative medicine.Blood Rev. 2013; 27: 77-89
- Interleukin-1 receptor antagonist activityof a human interleukin-1 inhibitor.Nature. 1990; 343: 336-340
- Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.Nature. 1990; 344: 633-638
- The production of anti-inflammatory cytokines in whole blood by physico-chemical induction.Inflamm Res. 2003; 52: 404-407
- Osteoarthritis: an update with relevance for clinical practice.Lancet. 2011; 377: 2115-2126
- Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains.Int J Sports Med. 2004; 25: 588-593
- Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.Am J Vet Res. 2007; 68: 290-296
- Comparison of double-bundle anterior cruciate ligament reconstruction with and without autologous conditioned serum application.Knee Surg Sports Traumatol Arthrosc. 2016; 24: 3377
- Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection.Arthritis Res Ther. 2010; 12: R114
- Treatment of osteoarthritis of the knee with a combination of autologous conditioned serum and physiotherapy: a two-year observational study.PLoS One. 2015; 10
- Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum.Dtsch Z Sportmed. 2003; 54: 209-221
- Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis.Osteoarthr Cartil. 2009; 17: 152-160
- Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial.Osteoarthr Cartil. 2008; 16: 498-505
- A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum.Orthop Rev (Pavia). 2013; 5: 59-64
- Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study.Spine (Phila Pa 1976). 2007; 32: 1803-1808
- Efficacy of epidural perineural injection of autologous conditioned serum in unilateral cervical radiculopathy: a pilot study.Spine (Phila Pa 1976). 2015; 40: E915-21
- Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains.Int J Sports Med. 2004; 25: 588-593
- Classifications in brief: Kellgren-Lawrence classification of osteoarthritis.Clin Orthop Relat Res. 2016; 474: 1886-1893
- Visual analogue scale (VAS).J Clin Nurs. 2001; 10: 697-706
- Bias and precision in visual analogue scales: a randomized controlled trial.Am J Epidemiol. 1999; 150: 1117-1127
- Long-term effect of injection treatment for osteoarthritis in the knee by Orthokin autologous conditioned serum.Cartilage. 2017; (1947603517743001)
- Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study.Rheumatology. 2002; 41: 1240-1248
- Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders.Br Med Bull. 2013; 105: 169-184
- Treatment of knee osteoarthritis with Orthokine-derived autologous conditioned serum.Expert Rev Clin Immunol. 2010; 6: 335-345
Article info
Publication history
Published online: August 08, 2018
Accepted:
July 14,
2018
Received in revised form:
June 25,
2018
Received:
March 23,
2018
Identification
Copyright
© 2018 Elsevier Ltd. All rights reserved.
